by Alexandre Beaurain | May 10, 2024 | Featured, News
PARIS, FRANCE, May 8, 2024 – Our CEO, Olivier Courrèges, will be presenting at the HITLAB Summit in New York City this week! Olivier’s presentation “AI Opening a New Era of Prediction and Monitoring for CNS Diseases.” is scheduled for May 8th at...
by Administrators Qynapse | Feb 28, 2024 | Featured, News
PARIS, FRANCE, February 28, 2024 – In the exciting context of effective new Alzheimer’s disease treatments, Qynapse are pleased to present our work at the upcoming AD/PD 2024 addressing the need for accurate standardized quantification of amyloid PET with...
by Administrators Qynapse | Sep 7, 2022 | Featured, News
BOSTON, MA, September 07, 2022 – Qynapse Inc., a medical technology company with a commercialized Artificial Intelligence (AI) powered neuroimaging analysis platform for central nervous system (CNS) disorders, is pleased to announce a collaborative project with...
by Administrators Qynapse | Aug 1, 2022 | News, Updates
We are excited to announce that 4 posters demonstrating the value and utility of automated neuroimaging quantification tool QyScore® are being presented by our Scientific Director Elizabeth Gordon at Alzheimer’s Association International Conference (AAIC) 2022...
by Administrators Qynapse | Jul 25, 2022 | Featured, News
Nottingham, England, Morrisville, NC, and Boston, MA–July 25, 2022 – Calyx, the eClinical and Regulatory solutions and services provider relied on for solving complex data challenges in clinical research and Qynapse, an Artificial Intelligence (AI) neuroimaging...
by Administrators Qynapse | Mar 3, 2022 | News
PARIS, FRANCE, March 3, 2022, PRNewswire – Qynapse SAS, a medical technology company commercializing an FDA approved/CE cleared AI-powered neuroimaging software platform for central nervous system (CNS) disorders, is pleased to announce that a symposium oral...
